CO2017008721A2 - Compuestos derivados de n-[[1,3,4-oxadiazol-2-il]tetrahidropiran-4-il]-n-metilbenzamida o n-[[1,2,4-triazol-3-il]tetrahidro-2h-piran-4-il]-n-metilbenzamida activos como agonistas de gpr142, composiciones que los comprenden y proceso para la producción de los mismos - Google Patents

Compuestos derivados de n-[[1,3,4-oxadiazol-2-il]tetrahidropiran-4-il]-n-metilbenzamida o n-[[1,2,4-triazol-3-il]tetrahidro-2h-piran-4-il]-n-metilbenzamida activos como agonistas de gpr142, composiciones que los comprenden y proceso para la producción de los mismos

Info

Publication number
CO2017008721A2
CO2017008721A2 CONC2017/0008721A CO2017008721A CO2017008721A2 CO 2017008721 A2 CO2017008721 A2 CO 2017008721A2 CO 2017008721 A CO2017008721 A CO 2017008721A CO 2017008721 A2 CO2017008721 A2 CO 2017008721A2
Authority
CO
Colombia
Prior art keywords
methylbenzamide
piran
oxadiazol
tetrahydropyran
triazol
Prior art date
Application number
CONC2017/0008721A
Other languages
English (en)
Inventor
zhi long Hu
Lian Zhu Liu
Tianwei Ma
Haizhen Zhang
Jingye Zhou
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2017008721A2 publication Critical patent/CO2017008721A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula siguiente: en donde R, R1-R3 son como se describen en la presente; métodos para tratar pacientes por diabetes usando los compuestos, y procesos para preparar los compuestos.
CONC2017/0008721A 2015-03-03 2017-08-28 Compuestos derivados de n-[[1,3,4-oxadiazol-2-il]tetrahidropiran-4-il]-n-metilbenzamida o n-[[1,2,4-triazol-3-il]tetrahidro-2h-piran-4-il]-n-metilbenzamida activos como agonistas de gpr142, composiciones que los comprenden y proceso para la producción de los mismos CO2017008721A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2015/073563 WO2016138631A1 (en) 2015-03-03 2015-03-03 Imidazo benzamide compounds
PCT/CN2016/074083 WO2016138821A1 (en) 2015-03-03 2016-02-19 Tetrahydropyranyl benzamide derivatives

Publications (1)

Publication Number Publication Date
CO2017008721A2 true CO2017008721A2 (es) 2018-01-05

Family

ID=56849060

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0008721A CO2017008721A2 (es) 2015-03-03 2017-08-28 Compuestos derivados de n-[[1,3,4-oxadiazol-2-il]tetrahidropiran-4-il]-n-metilbenzamida o n-[[1,2,4-triazol-3-il]tetrahidro-2h-piran-4-il]-n-metilbenzamida activos como agonistas de gpr142, composiciones que los comprenden y proceso para la producción de los mismos

Country Status (24)

Country Link
US (1) US10196385B2 (es)
EP (1) EP3265460A4 (es)
JP (1) JP2018507232A (es)
KR (1) KR20170106483A (es)
CN (1) CN107406436B (es)
AU (1) AU2016228055B2 (es)
BR (1) BR112017015448A2 (es)
CA (1) CA2975413A1 (es)
CL (1) CL2017002148A1 (es)
CO (1) CO2017008721A2 (es)
CR (1) CR20170354A (es)
DO (1) DOP2017000196A (es)
EA (1) EA201791745A1 (es)
EC (1) ECSP17058071A (es)
IL (1) IL253405A0 (es)
MA (1) MA41641A (es)
MX (1) MX2017011087A (es)
PE (1) PE20171650A1 (es)
PH (1) PH12017501560A1 (es)
SG (1) SG11201706718RA (es)
SV (1) SV2017005520A (es)
TN (1) TN2017000372A1 (es)
WO (2) WO2016138631A1 (es)
ZA (1) ZA201704948B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014337A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide
CA3089746A1 (en) 2018-03-09 2019-09-12 Recurium Ip Holdings, Llc Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007308154A1 (en) 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
JP5685181B2 (ja) * 2009-03-05 2015-03-18 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するシクロヘキサン誘導体
CA2785790A1 (en) * 2010-01-15 2011-07-21 Merck Sharp & Dohme Corp. Oxadiazole beta carboline derivatives as antidiabetic compounds
WO2012123449A1 (en) * 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators
WO2015120610A1 (en) 2014-02-14 2015-08-20 Eli Lilly And Company Gpr142 agonist compound

Also Published As

Publication number Publication date
US10196385B2 (en) 2019-02-05
US20180194755A1 (en) 2018-07-12
CR20170354A (es) 2017-09-05
DOP2017000196A (es) 2017-09-15
WO2016138631A1 (en) 2016-09-09
MA41641A (fr) 2018-01-09
SV2017005520A (es) 2018-08-27
EP3265460A4 (en) 2018-08-08
EP3265460A1 (en) 2018-01-10
WO2016138821A1 (en) 2016-09-09
EA201791745A1 (ru) 2018-01-31
CN107406436B (zh) 2021-02-26
CA2975413A1 (en) 2016-09-09
KR20170106483A (ko) 2017-09-20
JP2018507232A (ja) 2018-03-15
SG11201706718RA (en) 2017-09-28
AU2016228055B2 (en) 2018-06-07
AU2016228055A1 (en) 2017-08-17
PH12017501560A1 (en) 2018-02-05
CL2017002148A1 (es) 2018-04-13
PE20171650A1 (es) 2017-11-13
ZA201704948B (en) 2019-02-27
CN107406436A (zh) 2017-11-28
BR112017015448A2 (pt) 2018-01-30
ECSP17058071A (es) 2017-10-31
IL253405A0 (en) 2017-09-28
MX2017011087A (es) 2017-11-10
TN2017000372A1 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
DOP2021000179A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CO2017013229A2 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
GT201700035A (es) Compuestos aminopirimidinilo como inhibidores de jak
BR112018001400A2 (pt) compostos, processo para a síntese dos compostos, composição, utilização de um composto, método para o combate dos fungos e sementes
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
UY35572A (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4)
BR112017006116A2 (pt) processos de preparação de compostos e compostos
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
BR112018010140A2 (pt) compostos de fórmula, composição, utilização de um composto de fórmula, método para o combate de fungos fitopatogênicos e semente
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
BR112018006519A2 (pt) compostos de fórmula, processo para a síntese de compostos, compostos intermediários x, composição, utilização de um composto de fórmula, método para o combate de fungos e semente
BR112018010316A2 (pt) compostos de fórmula, composição, utilização de um composto de fórmula, método para o combate de fungos fitopatogênicos e semente
BR112019005886A2 (pt) tratamento com água de material lipídico
DOP2016000211A (es) Pirazinas moduladoras de gpr6
CL2014003443A1 (es) Compuestos derivados de n-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas; su metodo de produccion; compuestos intermediarios; producto medicinal que contiene al compuesto, util para el tratamiento y/o prevencion de enfermedades hiperproliferativas, las cuales son dependientes del receptor de androgenos.
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
CO2017008721A2 (es) Compuestos derivados de n-[[1,3,4-oxadiazol-2-il]tetrahidropiran-4-il]-n-metilbenzamida o n-[[1,2,4-triazol-3-il]tetrahidro-2h-piran-4-il]-n-metilbenzamida activos como agonistas de gpr142, composiciones que los comprenden y proceso para la producción de los mismos
BR112018074287A2 (pt) processo para preparação de eribulina e intermediários da mesma
BR112015031945A2 (pt) processos para a preparação de compostos
ECSP17046657A (es) Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina
BR112016011048A8 (pt) processo para preparar um composto, processos para fabricar compostos, compostos e composições farmacêuticas